丽珠医药(01513)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01513 丽珠医药

休市中 06-12 16:08:21

27.220

+0.780

+2.95%

最高27.500	最低26.320	成交量218.77万
今开26.320	昨收26.440	日振幅4.46%
总市值241.71亿	流通市值81.66亿	总股本8.88亿
成交额5,946万	换手率0.73%	流通股本3.00亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01513","market":"HK","secType":"STK","nameCN":"丽珠医药","latestPrice":27.22,"timestamp":1781251701003,"preClose":26.44,"halted":0,"volume":2187707,"delay":0,"changeRate":0.02950075642965195,"floatShares":300000000,"shares":888000000,"eps":2.27,"marketStatus":"休市中","change":0.78,"latestTime":"06-12 16:08:21","open":26.32,"high":27.5,"low":26.32,"amount":59457645,"amplitude":0.044629,"askPrice":27.24,"askSize":2500,"bidPrice":27.22,"bidSize":4300,"shortable":3,"etf":0,"ttmEps":2.505398,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781487000000},"marketStatusCode":7,"adr":0,"listingDate":1389801600000,"exchange":"SEHK","adjPreClose":26.44,"dividendRate":0.060498,"openAndCloseTimeList":[[1781227800000,1781236800000],[1781240400000,1781251200000]],"volumeRatio":2.872347744863693,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"000513","market":"SZ","secType":"STK","nameCN":"丽珠集团","latestPrice":31.87,"timestamp":1781247600000,"preClose":31.38,"halted":0,"volume":7738300,"delay":0,"premium":"-26.28"}},"requestUrl":"/m/hq/s/01513/tweets","defaultTab":"tweets","newsList":[{"id":"2642844597","title":"港股异动 | 丽珠医药(01513)尾盘涨近4% 莱康奇塔单抗注射液上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2642844597","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642844597?lang=zh_cn&edition=full","pubTime":"2026-06-10 15:31","pubTimestamp":1781076702,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，丽珠医药(01513)尾盘涨近4%，截至发稿，涨3.62%，报26.34港元，成交额1849.09万港元。消息面上，丽珠集团近日宣布，其1类创新生物药莱康奇塔单抗用于治疗强直性脊柱炎的上市申请，已获国家药品监督管理局正式受理。这是该药物继银屑病适应症上市申请获受理并纳入优先审评后，斩获的第二项 NDA 受理。公开资料显示，莱康奇塔单抗是中国首个自主研发的IL-17A/F双抗。随着后续适应症的逐步获批，莱康奇塔单抗将进一步丰富丽珠医药在自免领域的产品矩阵，提升公司在全球生物医药市场的竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","VXUS","BK1191","01513","IPOS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640995865","title":"港股公告掘金 | 智谱拟发行A股并在科创板上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2640995865","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640995865?lang=zh_cn&edition=full","pubTime":"2026-06-02 09:00","pubTimestamp":1780362051,"startTime":"0","endTime":"0","summary":"重大事项：丽珠医药：重组人促卵泡激素注射液获得《药品注册证书》山东新华制药股份：获得碳酸司维拉姆干混悬剂药品注册证书白云山：白云山制药总厂收到国家药监局核准签发的关于磷酸奥司他韦干混悬剂的《药品注册证书》智谱拟发行A股并在科创板上市驭势科技：与赛力斯凤凰智创完成行泊一体乘用车海外量产及交付澜起科技：横琴公司拟进行增资扩股并引入新投资方 引资合共约5亿元股东持续赋能!","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448875.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999015952.SGD","LU1328277881.USD","LU1770034418.SGD","BK1589","BK1610","IE00B543WZ88.USD","LU0315179316.USD","LU1868838027.USD","LU0700851271.USD","LU0214875030.USD","MPNGY","LU0593848301.USD","SG9999001226.SGD","LU0543330566.HKD","LU0455707207.USD","LU0880133367.SGD","BK1142","BYDDY","LU0196878994.USD","LU0289961442.SGD","LU0499858602.USD","LU2153592121.USD","01511","LU0819121731.USD","BK1509","LU0588545490.SGD","LU2257852520.SGD","LU2348774022.SGD","601127","LU2357125470.USD","SG9999001903.USD","LU1323998911.USD","IE0034224299.USD","LU0577902538.SGD","LU2506951792.HKD","002594","LU0269904917.USD","LU0320764755.SGD","LU0165289439.USD","LU0251144936.SGD","LU0128522157.USD","LU2152927971.USD","LU0865486749.SGD","LU2476274308.USD","BK1588","IE00BPRC5H50.USD","02513","BK1515","LU0516422366.SGD","01211","LU1993786604.SGD","LU0540923850.HKD","LU0231483743.USD","688008","BK1221","LU1282651048.USD","LU1102505762.USD","LU0326950275.SGD","HMTD.SI","LU0117841782.USD","LU2097828714.EUR","LU0348814723.USD","LU0431992006.USD","LU1105468828.SGD","LU1807302812.USD","LU0577902371.SGD","LU1224444064.USD","IE0032431581.USD","82333","LU2148510915.USD","LU2097828805.USD","LU0469268626.HKD","LU1224709979.USD","LU0501845795.SGD","LU0067412154.USD","HYDD.SI","BK1163","LU0856984785.SGD","BK1540","02886","BK1591","LU0143863198.USD","BK1521","NIO","LU0106252389.USD","BK1575","LU1720050803.USD","LU0039217434.USD","BK1606","LU0828238088.HKD","LU1481107354.HKD","LU2097828474.EUR","LU0605514214.HKD","LU0417516738.SGD","LU0084288322.USD","LU2249611893.SGD","LU0181495838.USD","LU1675838814.USD","LU0348735423.USD","LU1688375341.USD","LU1813983027.USD","LU0348825331.USD","LU0293314216.USD","LU0345776255.USD","LU2045819591.USD","LU0634319403.HKD","LU0051755006.USD","LU0370786039.SGD","00719","LU2226246903.HKD","000513","LU0054450605.USD","LU0289739343.SGD","03690","LU0819123356.HKD","LU0456827905.SGD","LU2087589342.USD","LU0140636845.USD","LU0577902611.USD","SG9999014674.SGD","LU1102505929.USD","LU0456846285.SGD","LU0047713382.USD","LU1008478684.HKD","LU0594300419.USD","LU1152091754.HKD","601633","LU0054237671.USD","SG9999001689.USD","LU1794554557.SGD","LU0011963245.USD","LU0823038988.USD","SG9999006597.SGD","LU1770036033.HKD","BK1582","IE00BF5LJ272.USD","BK1587","LU0708995583.HKD","LU0359201612.USD","LU1880383366.USD","07489","LU0541502299.USD","LU0228659784.USD","000756","IE00B5MMRT66.SGD","00175","LU0873338254.USD","LU0633140560.USD","LU0577902298.EUR","LU2097828557.USD","IE00B29SXG58.USD","LU0708995153.HKD","BK1522","LU0307460666.USD","81211","LU0143863784.USD","LU0611395673.USD","LU0048580855.USD","LU0828237940.HKD","LU0229945570.USD","LU0823414478.USD","LU0871576103.HKD","LU0149721374.USD","LU0072462343.USD","09868","LU0287142896.SGD","LU0320764243.SGD","LU0029875118.USD","LU0918141887.USD","IE00B0JY6N72.USD","LU2399975544.HKD","SG9999015986.USD","LU0261950983.USD","LU0511384066.AUD","LU0173614495.USD","SG9999002562.SGD","09927","LU0132412106.USD","LU1251922891.USD","LU1861219969.SGD","LU0327786744.USD","GELYY","SG9999015978.USD","IE0008368742.USD","LU0509642566.USD","LU0502904849.HKD","LU0823040885.USD","IE00B031HY20.USD","LU0577902454.USD","LU0164872284.USD","LU0683595622.HKD","LU0348827113.USD","LU0823039010.USD","LU0048597586.USD","LU1023057109.AUD","LU0878005551.USD","IE00BZ08YS42.EUR","LU1064130708.USD","LU1226287529.USD","LU1048588211.SGD","LU0823426480.USD","IE00BD6J9T35.USD","LU1831875114.USD","LU0463099449.HKD","600332","LU0633140727.USD","IE00BZ08YR35.GBP","LU0531971595.HKD","BK1119","LU1064131003.USD","LU2125910500.SGD","LU0259732245.USD","BK1233","LU0359202008.SGD","LU1719994722.HKD","LU0254981946.USD","LU2360107325.USD","BK1191","LU0588545730.USD","09973","LU0029874905.USD","LU0449515922.USD","LU2242644610.SGD","LU0052750758.USD","SG9999000459.SGD","LU0210526637.USD","EVS.SI","LU2097828631.EUR","LU0314109678.HKD","XPEV","LU2294711713.HKD","LU0821914370.USD","LU0043850808.USD","BK1604","BK1539","LU1303224171.USD","LU0164880469.USD","LU1328615791.USD","LU0828237510.HKD","LU1808992512.USD","LU0588546209.SGD","LU0543330483.HKD","LU0244354667.USD","IE0008369823.USD","BK1583","00874","LU2039709279.SGD","LU0868486357.SGD","LU0072913022.USD","LU0359201885.HKD","LU0797268264.HKD","LU0326948709.USD","LU0672654166.SGD","SG9999006514.SGD","LU2476274720.SGD","02333","SG9999002828.SGD","IE00BZ08YT58.USD","METmain","LU0823414551.USD","LU0572944931.SGD","LU1960683339.HKD","LU0516422440.USD","LU0128522744.USD","LU0594300179.USD","BK1618","NIO.SI","BK1615","LU1188198961.HKD","LU0499858438.USD","LU0348805143.USD","BK1117","BK1594","LU0516423174.USD","LU0211977185.USD","GWLLY","BK1197","LU1961090484.USD","LU1242518857.USD","LU0505663152.USD","LU1282648689.USD","LU0348816934.USD","LU0650527681.SGD","LU2449936058.SGD","LU0164865239.USD","LU0541501648.USD","01513","LU0417516902.SGD","LU1868837722.USD","09866","LU0049853897.USD","LU0589944569.HKD","LU2488822045.USD","LU1868837565.USD","LU1048596156.SGD","LU1242518931.SGD","LU0348788117.USD","06809","LU0588545904.SGD","80175","LU0289960550.SGD","LU0561508036.HKD","SG9999002463.SGD","LU2778985437.USD","LU0737861699.HKD","SG9999015945.SGD","LU0345775950.USD","LU1734074674.USD","SG9999000327.SGD","LU1861214812.USD","LU0320764599.SGD","LU0918141705.HKD","LU0531970944.HKD","LU1282651121.HKD","LU0979878070.USD","LU0516423091.SGD","LU0516422952.EUR","IE00B3M56506.USD","LU0449509016.USD","LU0315178854.USD","LU0823426308.USD","LU1880383440.USD","LU0823041008.USD","LU1152091168.USD","LU0175139822.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640957430","title":"丽珠医药(01513)：重组人促卵泡激素注射液获得《药品注册证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2640957430","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640957430?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:01","pubTimestamp":1780322506,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠医药 发布公告，近日，丽珠医药集团股份有限公司(本公司)的控股子公司珠海市丽珠单抗生物技术有限公司的药品重组人促卵泡激素注射液(本品)收到国家药品监督管理局核准签发的《药品注册证书》。截至本公告披露日，重组人促卵泡激素注射液累计直接投入的研发费用约为人民币1.217亿元。根据药监局及药品审评中心网站数据库显示，截至本公告披露日，重组人促卵泡激素注射液国内有4个进口产品及4个国产产品上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448778.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01513","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640895713","title":"丽珠医药(01513)：莱康奇塔单抗注射液上市许可申请获国家药品监督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2640895713","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640895713?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:00","pubTimestamp":1780322419,"startTime":"0","endTime":"0","summary":"莱康奇塔单抗注射液此次用于治疗强直性脊柱炎的上市申请已获国家药监局正式受理，是本品继银屑病适应症申请获受理并纳入优先审评后，第二项获受理的适应症。本品上市申请基于关键注册性III期临床研究，采用多中心、随机、双盲、安慰剂对照试验。截至本公告披露日，莱康奇塔单抗注射液累计直接投入的研发费用约为人民币21,693万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448777.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01513","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172103414","title":"丽珠医药5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1172103414","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172103414?lang=zh_cn&edition=full","pubTime":"2026-06-01 16:49","pubTimestamp":1780303762,"startTime":"0","endTime":"0","summary":"丽珠医药集团股份有限公司于2026年6月1日发布截至2026年5月31日止的月报表。报告显示，本月公司已发行普通股总数与上月相比无增减变动，股本结构保持稳定。根据公告，丽珠医药H股上月底与本月底的已发行股份数均为299,807,117股，A股上月底与本月底亦均为588,100,054股。公司确认已符合香港联交所的公眾持股量要求，并遵守上市规则及相关法律规定。本次公告由公司秘书刘宁签署。至本月底，丽珠医药股本总数保持不变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639627096","title":"丽珠医药(01513)选举冉永梅为第十二届董事会职工代表董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2639627096","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639627096?lang=zh_cn&edition=full","pubTime":"2026-05-29 20:48","pubTimestamp":1780058886,"startTime":"0","endTime":"0","summary":"智通财经APP许，丽珠医药(01513)发布公告，经会议表决，选举冉永梅女士为公司第十二届董事会职工代表董事。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448016.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118321227","title":"丽珠医药宣派末期股息每10股派16.43港元，7月13日派发","url":"https://stock-news.laohu8.com/highlight/detail?id=1118321227","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118321227?lang=zh_cn&edition=full","pubTime":"2026-05-29 20:35","pubTimestamp":1780058148,"startTime":"0","endTime":"0","summary":"丽珠医药(01513)发布末期股息更新公告，确认以港币派发的金额及汇率。公司2025年度末期股息为每10股派发现金红利14.3元人民币，经股东大会批准后，按1人民币兑1.149港元的汇率计算，折合每10股派发16.43港元。\n除净日定于2026年6月16日，为符合获取股息分派而递交股份过户文件的最后时限为2026年6月17日16:30，权益登记日为同日。股息预计于2026年7月13日派发。\n代扣所得税方面，对于非居民企业（非中国内地登记地址）股东，适用税率分别为10%或20%。香港股份过户登记处为卓佳证券登记有限公司。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"丽珠医药宣派末期股息每10股派16.43港元，7月13日派发","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639627411","title":"丽珠医药(01513)将于7月13日派发末期股息每10股14.3元","url":"https://stock-news.laohu8.com/highlight/detail?id=2639627411","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639627411?lang=zh_cn&edition=full","pubTime":"2026-05-29 20:33","pubTimestamp":1780058031,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠医药(01513)发布公告，该公司将于2026年7月13日派发末期股息每10股14.3元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448004.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VIG","BK4588","BK4585","BK1191","01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639462710","title":"丽珠医药(01513)聘任刘大平为总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2639462710","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639462710?lang=zh_cn&edition=full","pubTime":"2026-05-29 20:31","pubTimestamp":1780057888,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠医药 公布，于 2025 年度股东会上，董事会重选朱保国先生、林楠棋先生及邱庆丰先生为第十二届董事会非执行董事;重选唐阳刚先生以及选举刘大平先生为第十二届董事会执行董事;及重选罗会远先生、崔丽婕女士、王智瑶女士以及选举康立女士为第十二届董事会独立非执行董事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448002.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"丽珠医药(01513)聘任刘大平为总裁","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01513","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168777681","title":"丽珠医药宣派年度股息每股1.43元，7月13日派发","url":"https://stock-news.laohu8.com/highlight/detail?id=1168777681","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168777681?lang=zh_cn&edition=full","pubTime":"2026-05-29 20:26","pubTimestamp":1780057571,"startTime":"0","endTime":"0","summary":"丽珠医药于2026年5月29日举行股东周年大会，审议通过2025年度利润分配预案，将向全体股东每10股派发现金股利人民币14.30元（含税），折合每股1.43元。H股股息将以港币派付，按股东大会当日中国人民银行公布的人民币兑港币中间价1港元兑0.8703元人民币计算，每10股H股股息约16.43港元（含税）。在预扣税安排上，向H股非居民企业股东派息时将代扣代缴10%企业所得税；外籍个人股东暂免征收个人所得税。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"丽珠医药宣派年度股息每股1.43元，7月13日派发","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132212216","title":"丽珠医药2026年4月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1132212216","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132212216?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:53","pubTimestamp":1778057616,"startTime":"0","endTime":"0","summary":"丽珠医药于2026年5月6日发布2026年4月股份变动月报。报告期为2026年4月1日至2026年4月30日。公告显示，丽珠医药截止报告期末的股本结构保持稳定，未有新增发行、购回或注销情况。公司本月发行在外股份及注册股本均未发生变化，总注册股本仍为人民币887,907,171元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143836837","title":"丽珠医药最新进展：LIAN SGP完成对越南IMP要约收购，持股升至67.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143836837","media":"公告速递","labels":["shareholding","merge","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143836837?lang=zh_cn&edition=full","pubTime":"2026-04-29 20:55","pubTimestamp":1777467357,"startTime":"0","endTime":"0","summary":"丽珠医药集团披露，其全资子公司 LIAN SGP HOLDING PTE.LTD. 已结束对越南上市企业 Imexpharm Corporation的公开要约收购。根据越南国家证券委员会相关规定，LIAN SGP 此次要约收购的价格为每股 57,400 越南盾，对应约人民币 15.37 元。要约期间结束后，LIAN SGP 实际收购 104,545,781 股，占 IMP 注册资本的 67.87%，相当于有表决权股份的 67.88%。截至公告日，丽珠医药董事会成员包括执行董事唐阳刚、非执行董事朱保国（董事长）等多人，信息披露符合监管要求。公司将继续跟进交易后续事宜并依法履行信息披露义务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630870132","title":"国产司美格鲁肽“首证”缓发？多家申报企业称专利悬崖过后还有数据保护期","url":"https://stock-news.laohu8.com/highlight/detail?id=2630870132","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630870132?lang=zh_cn&edition=full","pubTime":"2026-04-25 17:05","pubTimestamp":1777107938,"startTime":"0","endTime":"0","summary":"司美格鲁肽保护期的延长或将导致国产司美的“内卷”进一步加剧。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260425/20260425170827_99857.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260425/20260425170827_99857.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433942.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0028","01513","BK0187","BK4007","NVOH","LU1093756168.USD","BK4585","000513","LU0154236417.USD","02566","LLY","BK4599","LU1093756325.SGD","BK4588","IE00BKVL7J92.USD","BK1161","NVOX","BK0239","NVO","BK0188","IE00BZ1G4Q59.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1180743900","title":"丽珠医药将于2026年7月13日派发末期股息每股1.43元","url":"https://stock-news.laohu8.com/highlight/detail?id=1180743900","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180743900?lang=zh_cn&edition=full","pubTime":"2026-04-23 22:41","pubTimestamp":1776955319,"startTime":"0","endTime":"0","summary":"丽珠医药(01513)发布公告称，将于2026年7月13日向于2026年6月17日登记在册的股东派发2025年12月31日止年度末期股息。每10股派14.3元人民币，折合每股1.43元人民币。\n股东批准日期为2026年5月29日，除净日定于2026年6月16日，股权登记的最后时限为2026年6月17日16时30分。公告显示，本次股息派发所涉非中国内地登记地址非居民企业将分别预扣10%或20%的所得税。\n根据公告，董事会成员包括执行董事唐阳刚，非执行董事朱保国、林楠棋、邱庆丰，职工董事冉永梅及独立非执行董事白华、罗会远、崔丽婕、王智瑶。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"丽珠医药将于2026年7月13日派发末期股息每股1.43元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629853891","title":"丽珠医药(01513)将于7月13日派发末期股息每10股14.3元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629853891","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629853891?lang=zh_cn&edition=full","pubTime":"2026-04-23 22:37","pubTimestamp":1776955066,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠医药(01513)发布公告，将于2026年7月13日派发2025年12月31日止年度末期股息每10股14.3元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432985.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK4588","01513","BK4585","VIG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629583061","title":"丽珠医药(01513)一季度归母净利润5.77亿元，同比下降9.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629583061","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629583061?lang=zh_cn&edition=full","pubTime":"2026-04-23 21:48","pubTimestamp":1776952092,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠医药 发布公告，2026年第一季度，公司实现营业收入人民币28.71亿元，同比下降9.73%;归属于上市公司股东的净利润人民币5.77亿元，同比下降9.39%。受行业政策调整过渡期的影响和一季度流感、呼吸道感染发病率等季节波动性影响，公司营业收入同比有所波动，但公司整体经营表现稳健，核心业务的经营质量保持坚挺。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432942.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104522755","title":"丽珠医药2026年第一季度营收28.71亿元，经调整净利润5.79亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1104522755","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104522755?lang=zh_cn&edition=full","pubTime":"2026-04-23 21:41","pubTimestamp":1776951690,"startTime":"0","endTime":"0","summary":"2026年第一季度，丽珠医药实现营业收入28.71亿元，同比下降9.73%。经调整净利润为5.79亿元，同比下降6.48%。经营活动产生的现金流量净额为8.17亿元，同比增长12.80%。从成本结构来看，本期销售费用为7.35亿元，同比下降约8.06%；管理费用为1.33亿元，同比下降约13.25%；研发费用为1.69亿元，同比下降约21.60%，占营业收入的约5.90%。公司表示，一季度营收波动主要受流感及呼吸道感染发病率回落、部分集采品种价格体系调整过渡、以及原料药板块订单季节性影响所致。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"丽珠医药2026年第一季度营收28.71亿元，经调整净利润5.79亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629839208","title":"丽珠医药(01513)提名刘大平、唐阳刚为执行董事候选人","url":"https://stock-news.laohu8.com/highlight/detail?id=2629839208","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629839208?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:12","pubTimestamp":1776946328,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠医药(01513)发布公告，鉴于公司第十一届董事会任期将于2026年6月20日届满，经与会董事认真审议，一致同意提名朱保国先生、林楠棋先生及邱庆丰先生为公司第十二届董事会非执行董事候选人，提名刘大平先生、唐阳刚先生为公司第十二届董事会执行董事候选人。鉴于公司第十一届董事会任期将于2026年6月20日届满，经与会董事认真审议，一致同意提名罗会远先生、崔丽婕女士、康立女士、王智瑶女士为公司第十二届董事会独立董事候选人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01513","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627000107","title":"丽珠医药JP-1366根除幽门螺杆菌临床获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2627000107","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627000107?lang=zh_cn&edition=full","pubTime":"2026-04-13 09:14","pubTimestamp":1776042842,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月13日，丽珠医药官微宣布，公司研发的创新钾离子竞争性酸阻滞剂（P-CAB）JP-1366片用于根除幽门螺杆菌（Hp）的临床试验申请（IND）已获国家药品监督管理局（NMPA）正式批准。该药物的片剂用于反流性食管炎治疗已进入上市审评审批阶段，注射剂用于消化性溃疡出血治疗则处于Ⅱ期临床阶段。基于该药物现有研发基础，本次新增适应症获批后，可直接进入Ⅲ期临床试验阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604133702420395.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604133702420395.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","01513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626219671","title":"丽珠医药(01513)：JP-1366片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2626219671","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626219671?lang=zh_cn&edition=full","pubTime":"2026-04-10 18:05","pubTimestamp":1775815509,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠医药(01513)发布公告，近日，丽珠医药集团股份有限公司 Livzon Pharmaceutical Group Inc.*收到国家药品监督管理局核准签发的《药物临床试验批准通知书》(通知书编号：2026LP01115)，同意公司申报的申报的 JP-1366 片开展“与适当的抗生素联用以根除幽门螺杆菌”适应症的临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427160.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01513","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.livzon.com.cn","stockEarnings":[{"period":"1week","weight":0.0342},{"period":"1month","weight":0.0134},{"period":"3month","weight":-0.0173},{"period":"6month","weight":-0.1219},{"period":"1year","weight":-0.1373},{"period":"ytd","weight":-0.0456}],"compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.0294},{"period":"6month","weight":-0.0485},{"period":"1year","weight":0.0284},{"period":"ytd","weight":-0.0356}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"丽珠医药集团股份有限公司是一家主要从事医药产品的研发、生产及销售业务的中国公司。该公司的主要业务包括化学制剂、生物制品、原料药及中间体、中药制剂、诊断试剂和设备，以及商业发展和职能管理。该公司的主要产品品牌包括“壹丽安”（艾普拉唑肠溶片及注射用艾普拉唑钠）、“丽珠得乐”（枸橼酸铋钾）系列产品、“丽倍乐”（雷贝拉唑钠肠溶胶囊）、“维三联”（枸橼酸铋钾片/替硝唑片/克拉霉素片）、“贝依”（注射用醋酸亮丙瑞林微球）、“丽申宝”（注射用尿促卵泡素）、“乐宝得”（注射用尿促性素）、“丽福康”（注射用伏立康唑）等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.001134},{"month":2,"riseRate":0.538462,"avgChangeRate":0.025407},{"month":3,"riseRate":0.538462,"avgChangeRate":0.022432},{"month":4,"riseRate":0.692308,"avgChangeRate":0.031864},{"month":5,"riseRate":0.384615,"avgChangeRate":0.007591},{"month":6,"riseRate":0.538462,"avgChangeRate":0.002845},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.018444},{"month":8,"riseRate":0.5,"avgChangeRate":0.000715},{"month":9,"riseRate":0.454545,"avgChangeRate":0.011936},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.019823},{"month":11,"riseRate":0.583333,"avgChangeRate":0.03425},{"month":12,"riseRate":0.5,"avgChangeRate":-0.008149}],"exchange":"SEHK","name":"丽珠医药","nameEN":"LIVZON PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"丽珠医药(01513)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供丽珠医药(01513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"丽珠医药,01513,丽珠医药股票,丽珠医药股票老虎,丽珠医药股票老虎国际,丽珠医药行情,丽珠医药股票行情,丽珠医药股价,丽珠医药股市,丽珠医药股票价格,丽珠医药股票交易,丽珠医药股票购买,丽珠医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"丽珠医药(01513)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供丽珠医药(01513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}